$CKPT
Checkpoint Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000110465921063096 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $70.00K $970.0K
YoY Change -92.78% 177.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.370M $1.680M
YoY Change 41.07% -1.18%
% of Gross Profit
Research & Development $4.213M $2.635M
YoY Change 59.89% -42.48%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.586M $4.313M
YoY Change 52.7% -31.37%
Operating Profit -$6.518M -$3.341M
YoY Change 95.09% -43.68%
Interest Expense $10.00K $60.00K
YoY Change -83.33% 50.0%
% of Operating Profit
Other Income/Expense, Net $13.00K $60.00K
YoY Change -78.33% 42.86%
Pretax Income -$6.510M -$3.280M
YoY Change 98.48% -44.31%
Income Tax
% Of Pretax Income
Net Earnings -$6.505M -$3.281M
YoY Change 98.26% -44.3%
Net Earnings / Revenue -9292.86% -338.25%
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share $0.09 -$64.47K
COMMON SHARES
Basic Shares Outstanding 70.30M
Diluted Shares Outstanding 70.30M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.03M $21.48M
YoY Change 179.47% 51.8%
Cash & Equivalents $60.03M $21.48M
Short-Term Investments
Other Short-Term Assets $68.00K $750.0K
YoY Change -90.93% 874.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $61.43M $23.21M
YoY Change 164.67% 51.82%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $61.43M $23.21M
Total Long-Term Assets $0.00 $0.00
Total Assets $61.43M $23.21M
YoY Change 164.67% 51.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.528M $2.310M
YoY Change 52.73% -48.07%
Accrued Expenses $160.0K $120.0K
YoY Change 33.33% 9.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.255M $6.990M
YoY Change 3.79% -14.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.255M $6.990M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $7.255M $6.990M
YoY Change 3.79% -14.86%
SHAREHOLDERS EQUITY
Retained Earnings -$149.7M
YoY Change
Common Stock $7.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $54.18M $16.22M
YoY Change
Total Liabilities & Shareholders Equity $61.43M $23.21M
YoY Change 164.67% 51.82%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$6.505M -$3.281M
YoY Change 98.26% -44.3%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.657M -$4.540M
YoY Change 2.58% -44.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 23.92M -56.00K
YoY Change -42810.71% -115.77%
NET CHANGE
Cash From Operating Activities -4.657M -4.540M
Cash From Investing Activities
Cash From Financing Activities 23.92M -56.00K
Net Change In Cash 19.26M -4.596M
YoY Change -519.08% -41.44%
FREE CASH FLOW
Cash From Operating Activities -$4.657M -$4.540M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001651407
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Checkpoint Therapeutics, Inc.
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62420439
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72163822
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-38128
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2568632
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort Street
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
9th Floor
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
CY2021Q1 dei City Area Code
CityAreaCode
781
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
CKPT
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60033000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40772000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1329000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1804000
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
68000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
20000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
61430000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42596000
CY2021Q1 us-gaap Assets
Assets
61430000
CY2020Q4 us-gaap Assets
Assets
42596000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6076000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6367000
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1179000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
850000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7255000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7217000
CY2021Q1 us-gaap Liabilities
Liabilities
7255000
CY2020Q4 us-gaap Liabilities
Liabilities
7217000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72163822
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62420439
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q1 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
0
CY2020Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1742449
CY2020Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
4617000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
203864000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
173947000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149697000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143192000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
54175000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61430000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42596000
CY2021Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
68000
CY2020Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
972000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4213000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2635000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2373000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1678000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
6586000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
4313000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6518000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3341000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
60000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
60000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6505000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3281000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70303387
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50875476
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2021Q1 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
23893000
CY2021Q1 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
634000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
774000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6505000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
54175000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18847000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
639000
CY2020Q1 ckpt Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
13000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3281000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
16218000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6505000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3281000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
774000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
639000
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
634000
CY2020Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-475000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110000
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
48000
CY2020Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
946000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1062000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4657000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4540000
CY2021Q1 ckpt Issuance Of Common Shares At The Market Offering
IssuanceOfCommonSharesAtTheMarketOffering
24569000
CY2020Q1 ckpt Issuance Of Common Shares At The Market Offering
IssuanceOfCommonSharesAtTheMarketOffering
0
CY2021Q1 ckpt Payment Of Stock Offering Costs
PaymentOfStockOfferingCosts
651000
CY2020Q1 ckpt Payment Of Stock Offering Costs
PaymentOfStockOfferingCosts
0
CY2021Q1 ckpt Issuance Of Common Stock Public Offering
IssuanceOfCommonStockPublicOffering
0
CY2020Q1 ckpt Issuance Of Common Stock Public Offering
IssuanceOfCommonStockPublicOffering
-69000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23918000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-56000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19261000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4596000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40772000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26077000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60033000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21481000
CY2021Q1 us-gaap Stock Issued1
StockIssued1
4617000
CY2020Q1 us-gaap Stock Issued1
StockIssued1
0
CY2021Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
25000
CY2020Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149700000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2015Q1 ckpt Equity Method Investment Annual Equity Feepercentage
EquityMethodInvestmentAnnualEquityFeepercentage
0.025
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4503838
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8304230
CY2020Q2 ckpt Common Stock Increase In Shares Authorized
CommonStockIncreaseInSharesAuthorized
35000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 ckpt Shelf Registration Statement Maximum Authorized Securities
ShelfRegistrationStatementMaximumAuthorizedSecurities
100000000
CY2021Q1 ckpt Shelf Registration Statement Remaining Authorized Securities
ShelfRegistrationStatementRemainingAuthorizedSecurities
71300000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0104
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0102
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0271
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0127
CY2021Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
774000
CY2020Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
639000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3528000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3438000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
155000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
535000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2019000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2009000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
374000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
385000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6076000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6367000

Files In Submission

Name View Source Status
0001104659-21-063096-index-headers.html Edgar Link pending
0001104659-21-063096-index.html Edgar Link pending
0001104659-21-063096.txt Edgar Link pending
0001104659-21-063096-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20210331.xsd Edgar Link pending
tmb-20210331x10q.htm Edgar Link pending
tmb-20210331x10q_htm.xml Edgar Link completed
tmb-20210331xex31d1.htm Edgar Link pending
tmb-20210331xex31d2.htm Edgar Link pending
tmb-20210331xex32d1.htm Edgar Link pending
tmb-20210331xex32d2.htm Edgar Link pending
tmb-20210331_cal.xml Edgar Link unprocessable
tmb-20210331_def.xml Edgar Link unprocessable
tmb-20210331_lab.xml Edgar Link unprocessable
tmb-20210331_pre.xml Edgar Link unprocessable